Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
1.
Viruses ; 16(6)2024 May 27.
Article in English | MEDLINE | ID: mdl-38932149

ABSTRACT

DNA viruses that produce persistent infections have been proposed as potential causes for the extinction of Neanderthals, and, therefore, the identification of viral genome remnants in Neanderthal sequence reads is an initial step to address this hypothesis. Here, as proof of concept, we searched for viral remnants in sequence reads of Neanderthal genome data by mapping to adenovirus, herpesvirus and papillomavirus, which are double-stranded DNA viruses that may establish lifelong latency and can produce persistent infections. The reconstructed ancient viral genomes of adenovirus, herpesvirus and papillomavirus revealed conserved segments, with nucleotide identity to extant viral genomes and variable regions in coding regions with substantial divergence to extant close relatives. Sequence reads mapped to extant viral genomes showed deamination patterns of ancient DNA, and these ancient viral genomes showed divergence consistent with the age of these samples (≈50,000 years) and viral evolutionary rates (10-5 to 10-8 substitutions/site/year). Analysis of random effects showed that the Neanderthal mapping to genomes of extant persistent viruses is above what is expected by random similarities of short reads. Also, negative control with a nonpersistent DNA virus does not yield statistically significant assemblies. This work demonstrates the feasibility of identifying viral genome remnants in archaeological samples with signal-to-noise assessment.


Subject(s)
DNA, Ancient , Genome, Viral , Neanderthals , Animals , Neanderthals/genetics , Neanderthals/virology , DNA, Ancient/analysis , Evolution, Molecular , DNA, Viral/genetics , Sequence Analysis, DNA/methods , Humans , Phylogeny , DNA Viruses/genetics , DNA Viruses/classification , DNA Viruses/isolation & purification , Fossils/virology
2.
Int J Mol Sci ; 25(7)2024 Mar 28.
Article in English | MEDLINE | ID: mdl-38612593

ABSTRACT

The genetic contributions of Neanderthals to the modern human genome have been evidenced by the comparison of present-day human genomes with paleogenomes. Neanderthal signatures in extant human genomes are attributed to intercrosses between Neanderthals and archaic anatomically modern humans (AMHs). Although Neanderthal signatures are well documented in the nuclear genome, it has been proposed that there is no contribution of Neanderthal mitochondrial DNA to contemporary human genomes. Here we show that modern human mitochondrial genomes contain 66 potential Neanderthal signatures, or Neanderthal single nucleotide variants (N-SNVs), of which 36 lie in coding regions and 7 result in nonsynonymous changes. Seven N-SNVs are associated with traits such as cycling vomiting syndrome, Alzheimer's disease and Parkinson's disease, and two N-SNVs are associated with intelligence quotient. Based on recombination tests, principal component analysis (PCA) and the complete absence of these N-SNVs in 41 archaic AMH mitogenomes, we conclude that convergent evolution, and not recombination, explains the presence of N-SNVs in present-day human mitogenomes.


Subject(s)
Alzheimer Disease , Genome, Mitochondrial , Neanderthals , Humans , Animals , Neanderthals/genetics , Mutation , Nucleotides
3.
BMC Neurol ; 22(1): 439, 2022 Nov 18.
Article in English | MEDLINE | ID: mdl-36401198

ABSTRACT

BACKGROUND: Narcolepsy type 1 (NT1) is a rare and chronic neurological disease characterized by sudden sleep attacks, overwhelming daytime drowsiness, and cataplexy. When associated with a sudden loss of muscle tone (cataplexy) narcolepsy is classified as type 1, while the absence of cataplexy indicates type 2. Genetic, degenerative, and immunological hypotheses to explain the pathophysiology of NT1 are still a matter of debate. To contribute to the understanding of NT1 genetic basis, here we describe, for the first time, a whole genome analysis of a monozygotic twin pair discordant for NT1. CASE PRESENTATION: We present the case of a pair of 17-year-old male, monozygotic twins discordant for NT1. The affected twin had Epworth Sleepiness Scale (ESS) of 20 (can range from 0 to 24), cataplexy, hypnagogic hallucinations, polysomnography without abnormalities, multiple sleep latency tests (MSLT) positive for narcolepsy, a mean sleep latency of 3 min, sleep-onset REM periods SOREMPs of 5, presence of allele HLA-DQB1*06:02, and Hypocretin-1 level of zero pg/mL (normal values are > 200 pg/mL). The other twin had no narcolepsy symptoms (ESS of 4), normal polysomnography, MSLT without abnormalities, presence of allele HLA-DQB1*06:02, and Hypocretin-1 level of 396,74 pg/mL. To describe the genetic background for the NT1 discordant manifestations in this case, we present the whole-genome analysis of this monozygotic twin pair. The whole-genome comparison revealed that both twins have identical NT1 pathogenic mutations in known genes, such as HLA-DQB1*06:02:01, HLA-DRB1*11:01:02/*15:03:01. The affected twin has the expected clinical manifestation while the unaffected twin has an unexpected phenotype. The unaffected twin has significantly more frameshift mutations as compared to the affected twin (108 versus 75) and mutations that affect stop codons (61 versus 5 in stop gain, 26 versus 2 in start lost). CONCLUSIONS: The differences observed in frameshift and stop codon mutations in the unaffected twin are consistent with loss-of-function effects and protective alleles, that are almost always associated with loss-of-function rare alleles. Also, overrepresentation analysis of genes containing variants with potential clinical relevance in the unaffected twin shows that most mutations are in genes related to immune regulation function, Golgi apparatus, MHC, and olfactory receptor. These observations support the hypothesis that NT1 has an immunological basis although protective mutations in non-HLA alleles might interfere with the expression of the NT1 phenotype and consequently, with the clinical manifestation of the disease.


Subject(s)
Cataplexy , Narcolepsy , Male , Humans , Orexins , Brazil , Narcolepsy/diagnosis , Narcolepsy/genetics , Polysomnography
4.
Eur J Pain ; 26(4): 825-834, 2022 04.
Article in English | MEDLINE | ID: mdl-35044019

ABSTRACT

BCKGROUND: Aripiprazole is an antipsychotic drug used to treat schizophrenia and bipolar disorder. Recently, its peripheral analgesic component was evaluated, however, the mechanism involved in this effect is not fully established. Therefore, the aim of the study was to obtain pharmacological evidence for the involvement of the nitric oxide system in the peripheral antinociceptive effect induced by aripiprazole. METHODS: The hyperalgesia was induced via intraplantar injection of prostaglandin E2 in mice and the nociceptive thresholds were evaluated using the paw pressure test. All drugs were injected locally into the right hind paw. RESULTS: The PI3K inhibitor (AS605240), but not rapamycin (mTOR kinase inhibitor), reversed the peripheral antinociceptive effect induced by Aripiprazole. Antinociception was antagonized by the non-selective inhibitor of the nitric oxide synthase (L-NOarg). The same response was observed using the selective iNOS, but not with the selective nNOS inhibitors. The selective guanylyl cyclase enzyme inhibitor (ODQ) and the non-selective potassium channel blocker tetraethylammonium were able to reverse the antinociceptive effect of aripiprazole. The same was seen using glibenclamide, an ATP-dependent K+ channel blocker. However, calcium-activated potassium channel blockers of small and high conductance, dequalinium chloride and paxilline, respectively, did not reverse this effect. The injection of cGMP-specific phosphodiesterase type 5 inhibitor zaprinast, potentiated the antinociceptive effect induced by a low dose of aripiprazole. CONCLUSION: The results provide evidence that aripiprazole induces peripheral antinociceptive effects via PI3K/NO/cGMP/KATP pathway activation.


Subject(s)
Analgesics , Antipsychotic Agents , Aripiprazole , Adenosine Triphosphate , Analgesics/therapeutic use , Animals , Antipsychotic Agents/pharmacology , Aripiprazole/pharmacology , Class Ib Phosphatidylinositol 3-Kinase/metabolism , Cyclic GMP/metabolism , Mice , Nitric Oxide/metabolism
5.
Eur J Pharmacol ; 901: 174089, 2021 Jun 15.
Article in English | MEDLINE | ID: mdl-33826922

ABSTRACT

The participation of the peripheral opioid and cannabinoid endogenous systems in modulating muscle pain and inflammation has not been fully explored. Thus, the aim of this study was to investigate the involvement of these endogenous systems during muscular-tissue hyperalgesia induced by inflammation. Hyperalgesia was induced by carrageenan injection into the tibialis anterior muscles of male Wistar rats. We padronized an available Randal-Sellito test adaptation to evaluate nociceptive behavior elicited by mechanical insult in muscles. Western blot analysis was performed to evaluate the expression levels of opioid and cannabinoid receptors in the dorsal root ganglia. The non-selective opioid peptide receptor antagonist (naloxone) and the selective mu opioid receptor MOP (clocinnamox) and kappa opioid receptor KOP (nor-binaltorphimine) antagonists were able to intensify carrageenan-induced muscular hyperalgesia. On the other hand, the selective delta opioid receptor (DOP) antagonist (naltrindole) did not present any effect on nociceptive behavior. Moreover, the selective inhibitor of aminopeptidases (Bestatin) provoked considerable dose-dependent analgesia when intramuscularly injected into the hyperalgesic muscle. The CB1 receptor antagonist (AM251), but not the CB2 receptor antagonist (AM630), intensified muscle hyperalgesia. All irreversible inhibitors of anandamide hydrolase (MAFP), the inhibitor for monoacylglycerol lipase (JZL184) and the anandamide reuptake inhibitor (VDM11) decreased carrageenan-induced hyperalgesia in muscular tissue. Lastly, MOP, KOP and CB1 expression levels in DRG were baseline even after muscular injection with carrageenan. The endogenous opioid and cannabinoid systems participate in peripheral muscle pain control through the activation of MOP, KOP and CB1 receptors.


Subject(s)
Myalgia/drug therapy , Receptors, Cannabinoid/physiology , Receptors, Opioid/physiology , Animals , Arachidonic Acids/antagonists & inhibitors , Carrageenan , Cinnamates/pharmacology , Endocannabinoids/antagonists & inhibitors , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Hyperalgesia/psychology , Male , Monoacylglycerol Lipases/antagonists & inhibitors , Morphine Derivatives/pharmacology , Myalgia/chemically induced , Myalgia/psychology , Naloxone/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Pain Measurement/drug effects , Polyunsaturated Alkamides/antagonists & inhibitors , Rats , Rats, Wistar , Receptors, Cannabinoid/drug effects , Receptors, Opioid/drug effects , Receptors, Opioid, delta/drug effects , Receptors, Opioid, kappa/drug effects , Receptors, Opioid, mu/drug effects
6.
J Sch Health ; 90(4): 295-300, 2020 04.
Article in English | MEDLINE | ID: mdl-31989651

ABSTRACT

BACKGROUND: At a time and educational context favorable to technologies and innovations, we took the initiative to mobile phone applications (apps) relevant to school violence in an effort to be responsive to a growing public health problem in multiple countries. METHODS: In this study, we compared and verified the features of 10 apps for reporting violence in schools. We used a benchmarking tool for integrative review of these mobile apps. RESULTS: There were 13 apps on the Google Play platform, 11 apps in the App Store, and 5 apps on both platforms, totaling 19 apps. We selected 10 apps for comparative analysis. CONCLUSIONS: Through benchmarking, we determined the relevant features of the apps with recommendations for improving app development in the future.


Subject(s)
Bullying , Mobile Applications/statistics & numerical data , Schools , Violence , Benchmarking , Bullying/statistics & numerical data , Humans , Violence/statistics & numerical data
7.
Anesth Analg ; 129(1): 263-268, 2019 07.
Article in English | MEDLINE | ID: mdl-30198932

ABSTRACT

BACKGROUND: Recently, we demonstrated that the antipsychotic dopaminergic and serotoninergic agonist aripiprazole induced peripheral antinociception. However, the mechanism underlying this effect has not been fully established. Here, our aim was to identify possible relationships between this action of aripiprazole and the endocannabinoid system. METHODS: All drugs were given locally into the right hind paw of male Swiss mice weighing 30-35 g in a volume of 20 µL. The hyperalgesia was induced by intraplantar injection of prostaglandin E2 (2 µg). Aripiprazole was injected 10 minutes before the measurement, and an irreversible inhibitor of anandamide hydrolase (MAFP), an inhibitor for monoacylglycerol lipase (JZL184), and an anandamide reuptake inhibitor (VDM11) were given 10 minutes before the aripiprazole. Nociceptive thresholds were measured using an algesimetric apparatus in the third hour after prostaglandin E2 injection. Data were analyzed by ANOVA and Bonferroni tests. RESULTS: The antinociceptive effect induced by aripiprazole (100 µg) was blocked by cannabinoid 1 or 2 receptor antagonists AM251 (40 µg [P < .01], 80 µg [P < .0001], and 160 µg [P < .0001]) and AM630 (100 µg [P < .0001], 200 µg [P < .0001], and 400 µg [P < .0001]), respectively. The peripheral antinociception induced by aripiprazole (25 µg) was enhanced by administration of the inhibitor of fatty acid amide hydrolase (MAFP, 0.5 µg [P < .0001]) or monoacylglycerol lipase (JZL184, 4 µg [P < .0001]). Moreover, a similar enhancement was observed with the anandamide reuptake inhibitor (VDM11, 2.5 µg [P < .0001]). CONCLUSIONS: These results provide evidence for the involvement of the endocannabinoid system in peripheral antinociception induced by aripiprazole treatment.


Subject(s)
Analgesics/pharmacology , Aripiprazole/pharmacology , Cannabinoid Receptor Agonists/pharmacology , Endocannabinoids/metabolism , Hyperalgesia/prevention & control , Nociceptive Pain/prevention & control , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB2/agonists , Animals , Dinoprostone , Disease Models, Animal , Hyperalgesia/chemically induced , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Male , Mice , Nociceptive Pain/chemically induced , Nociceptive Pain/metabolism , Nociceptive Pain/physiopathology , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/metabolism , Signal Transduction
8.
Front Neurol ; 9: 39, 2018.
Article in English | MEDLINE | ID: mdl-29472887

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is the third most prevalent neurodegenerative disease affecting upper and lower motor neurons. An important pathway that may lead to motor neuron degeneration is neuroinflammation. Cerebrospinal Fluids of ALS patients have increased levels of the inflammatory cytokine IL-18. Because IL-18 is produced by dendritic cells stimulated by the platelet-activating factor (PAF), a major neuroinflammatory mediator, it is expected that PAF is involved in ALS. Here we show pilot experimental data on amplification of PAF receptor (PAFR) mRNA by RT-PCR. PAFR is overexpressed, as compared to age matched controls, in the spinal cords of transgenic ALS SOD1-G93A mice, suggesting PAF mediation. Although anti-inflammatory drugs have been tested for ALS before, no clinical trial has been conducted using PAFR specific inhibitors. Therefore, we hypothesize that administration of PAFR inhibitors, such as Ginkgolide B, PCA 4248 and WEB 2086, have potential to function as a novel therapy for ALS, particularly in SOD1 familial ALS forms. Because currently there are only two approved drugs with modest effectiveness for ALS therapy, a search for novel drugs and targets is essential.

9.
J Pain ; 19(5): 487-495, 2018 05.
Article in English | MEDLINE | ID: mdl-29247851

ABSTRACT

Ketamine has been widely used as an analgesic and produces dissociative anesthetic effects. The antinociceptive effects of ketamine have been studied, but the involvement of endocannabinoids in these effects has not yet been investigated. In this study, we evaluated the involvement of the endocannabinoid system in the peripheral antinociceptive effects induced by ketamine. All drugs were administered via the intraplantar route. To induce hyperalgesia, rat paws were injected with prostaglandin E2 (2 µg per paw). The nociceptive threshold for mechanical stimulation was measured in the right hind paw of Wistar rats using the Randall-Selitto test. The tissue levels of anandamide (AEA), 2-arachidonoylglycerol, palmitoylethanolamide, and oleoylethanolamide were measured using liquid chromatography coupled to single quadrupole mass spectrometry. The administration of the cannabinoid receptor type 1 (CB1) antagonist, N(piperidine-1yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl 1 pyrazolcarboxamide (20, 40, and 80 µg per paw), but not the cannabinoid receptor type 2 antagonist, 6-iodo-2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl) (4-methoxyphenyl) methanone (100 µg per paw), antagonized the ketamine-induced peripheral antinociception in a dose-dependent manner. Additionally, the administration of the endocannabinoid metabolizing enzyme inhibitor (.5 µg per paw) or an AEA reuptake inhibitor, (5Z,8Z,11Z,14Z)N(4Hydroxy2methylphenyl)5,8,11,14 eicosatetraenamide (2.5 µg per paw) significantly enhanced low-dose ketamine-induced peripheral antinociception. AEA paw levels were increased only after ketamine administration to prostaglandin E2-injected paws. These data suggest that ketamine, in the presence of a nociceptive stimulus, induces a selective release of AEA levels and subsequent CB1 cannabinoid activation at the peripheral level. PERSPECTIVE: This study suggests that ketamine antinociception depends at least in part on AEA release and CB1 cannabinoid receptor activation in inflammatory conditions. This study could potentially help clinicians in the use of ketamine as a peripheral analgesic for inflammatory pain.


Subject(s)
Analgesics/therapeutic use , Endocannabinoids/metabolism , Ketamine/therapeutic use , Pain/drug therapy , Pain/metabolism , Receptor, Cannabinoid, CB1/metabolism , Analgesics/pharmacology , Animals , Arachidonic Acids/metabolism , Cannabinoid Receptor Agonists/pharmacology , Cannabinoid Receptor Agonists/therapeutic use , Cannabinoid Receptor Antagonists/pharmacology , Cannabinoid Receptor Antagonists/therapeutic use , Ketamine/pharmacology , Male , Polyunsaturated Alkamides/metabolism , Rats , Rats, Wistar , Receptor, Cannabinoid, CB1/agonists
10.
J Biol Chem ; 292(6): 2422-2440, 2017 02 10.
Article in English | MEDLINE | ID: mdl-28028172

ABSTRACT

Histone acetylation has a regulatory role in gene expression and is necessary for proper tissue development. To investigate the specific roles of histone deacetylases (HDACs) in rod differentiation in neonatal mouse retinas, we used a pharmacological approach that showed that inhibition of class I but not class IIa HDACs caused the same phenotypic changes seen with broad spectrum HDAC inhibitors, most notably a block in the differentiation of rod photoreceptors. Inhibition of HDAC1 resulted in increase of acetylation of lysine 9 of histone 3 (H3K9) and lysine 12 of histone 4 (H4K12) but not lysine 27 of histone 3 (H3K27) and led to maintained expression of progenitor-specific genes such as Vsx2 and Hes1 with concomitant block of expression of rod-specific genes. ChiP experiments confirmed these changes in the promoters of a group of progenitor genes. Based on our results, we suggest that HDAC1-specific inhibition prevents progenitor cells of the retina from exiting the cell cycle and differentiating. HDAC1 may be an essential epigenetic regulator of the transition from progenitor cells to terminally differentiated photoreceptors.


Subject(s)
Cell Differentiation , Histone Deacetylase 1/metabolism , Histones/metabolism , Lysine/metabolism , Retina/metabolism , Retinal Rod Photoreceptor Cells/chemistry , Acetylation , Animals , Apoptosis , Gene Expression Regulation , Histone Deacetylase Inhibitors/pharmacology , Histones/chemistry , Mice , Mice, Inbred C57BL , Promoter Regions, Genetic , Rhodopsin/metabolism
11.
Toxins (Basel) ; 8(4): 106, 2016 Apr 12.
Article in English | MEDLINE | ID: mdl-27077886

ABSTRACT

PnTx4(6-1), henceforth renamed δ-Ctenitoxin-Pn1a (δ-CNTX-Pn1a), a peptide from Phoneutria nigriventer spider venom, initially described as an insect toxin, binds to site 3 of sodium channels in nerve cord synaptosomes and slows down sodium current inactivation in isolated axons in cockroaches (Periplaneta americana). δ-CNTX-Pn1a does not cause any apparent toxicity to mice, when intracerebroventricularly injected (30 µg). In this study, we evaluated the antinociceptive effect of δ-CNTX-Pn1a in three animal pain models and investigated its mechanism of action in acute pain. In the inflammatory pain model, induced by carrageenan, δ-CNTX-Pn1a restored the nociceptive threshold of rats, when intraplantarly injected, 2 h and 30 min after carrageenan administration. Concerning the neuropathic pain model, δ-CNTX-Pn1a, when intrathecally administered, reversed the hyperalgesia evoked by sciatic nerve constriction. In the acute pain model, induced by prostaglandin E2, intrathecal administration of δ-CNTX-Pn1a caused a dose-dependent antinociceptive effect. Using antagonists of the receptors, we showed that the antinociceptive effect of δ-CNTX-Pn1a involves both the cannabinoid system, through CB1 receptors, and the opioid system, through µ and δ receptors. Our data show, for the first time, that δ-Ctenitoxin-Pn1a is able to induce antinociception in inflammatory, neuropathic and acute pain models.


Subject(s)
Acute Pain/drug therapy , Analgesics/therapeutic use , Arthropod Proteins/therapeutic use , Hyperalgesia/drug therapy , Neuralgia/drug therapy , Peptides/therapeutic use , Acute Pain/metabolism , Analgesics/pharmacology , Animals , Arthropod Proteins/pharmacology , Cannabinoid Receptor Antagonists/pharmacology , Carrageenan , Dinoprostone , Hyperalgesia/chemically induced , Hyperalgesia/metabolism , Male , Narcotic Antagonists/pharmacology , Neuralgia/chemically induced , Neuralgia/metabolism , Peptides/pharmacology , Rats, Wistar , Receptors, Cannabinoid/metabolism , Receptors, Opioid/metabolism , Sciatic Nerve/injuries , Spider Venoms/chemistry , Spiders
12.
Math Biosci ; 276: 82-100, 2016 06.
Article in English | MEDLINE | ID: mdl-27036626

ABSTRACT

Here we propose a new approach to modeling gene expression based on the theory of random dynamical systems (RDS) that provides a general coupling prescription between the nodes of any given regulatory network given the dynamics of each node is modeled by a RDS. The main virtues of this approach are the following: (i) it provides a natural way to obtain arbitrarily large networks by coupling together simple basic pieces, thus revealing the modularity of regulatory networks; (ii) the assumptions about the stochastic processes used in the modeling are fairly general, in the sense that the only requirement is stationarity; (iii) there is a well developed mathematical theory, which is a blend of smooth dynamical systems theory, ergodic theory and stochastic analysis that allows one to extract relevant dynamical and statistical information without solving the system; (iv) one may obtain the classical rate equations form the corresponding stochastic version by averaging the dynamic random variables (small noise limit). It is important to emphasize that unlike the deterministic case, where coupling two equations is a trivial matter, coupling two RDS is non-trivial, specially in our case, where the coupling is performed between a state variable of one gene and the switching stochastic process of another gene and, hence, it is not a priori true that the resulting coupled system will satisfy the definition of a random dynamical system. We shall provide the necessary arguments that ensure that our coupling prescription does indeed furnish a coupled regulatory network of random dynamical systems. Finally, the fact that classical rate equations are the small noise limit of our stochastic model ensures that any validation or prediction made on the basis of the classical theory is also a validation or prediction of our model. We illustrate our framework with some simple examples of single-gene system and network motifs.


Subject(s)
Gene Expression/genetics , Gene Regulatory Networks/genetics , Models, Genetic , Animals , Humans
13.
Eur J Pharmacol ; 765: 300-6, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26325094

ABSTRACT

Aripiprazole is an antipsychotic that acts by multiple mechanisms, including partial agonism at dopamine D2 and serotonin 5-HT1A receptors. Since these neurotransmitters also modulate pain and analgesia, we tested the hypothesis that systemic or local administration of aripiprazole induces antinociceptive responses. Systemic aripiprazole (0.1-10 mg/kg; i.p.) injection in mice inhibited formalin-induced paw licking and PGE2-induced hyperalgesia in the paw pressure test. This effect was mimicked by intra-plantar administration (12.5-100 µg/paw) in the ipsi, but not contralateral, paw. The peripheral action of aripiprazole (100 µg/paw) was reversed by haloperidol (0.1-10 µg/paw), suggesting the activation of dopamine receptors as a possible mechanism. Accordingly, quinpirole (25-100 µg/paw), a full agonist at D2/D3 receptors, also reduced nociceptive responses.. In line with the partial agoniztic activity of aripiprazole, low dose of this compound inhibited the effect of quinpirole (both at 25 µg/paw). Finally, peripheral administration of NAN-190 (0.1-10 µg/paw), a 5-HT1A antagonist, also prevented aripiprazole-induced antinociception. In conclusion, systemic or local administration of aripiprazole induces antinociceptive effects. Similar to its antipsychotic activity, the possible peripheral mechanism involves dopamine D2 and serotoninergic 5-HT1A receptors. Aripiprazole and other dopaminergic modulators should be further investigated as new treatments for certain types of pain.


Subject(s)
Analgesics/pharmacology , Antipsychotic Agents/pharmacology , Aripiprazole/pharmacology , Receptor, Serotonin, 5-HT1A/metabolism , Receptors, Dopamine D2/metabolism , Animals , Dose-Response Relationship, Drug , Injections, Intraperitoneal , Male , Mice , Pain Measurement , Pain Threshold/drug effects , Receptors, Dopamine D2/agonists
14.
Infect Genet Evol ; 31: 198-208, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25660041

ABSTRACT

Benznidazole (BZ) is one of the two drugs for Chagas disease treatment. In a previous study we showed that the Trypanosoma cruzi ABCG-like transporter gene, named TcABCG1, is over-expressed in parasite strains naturally resistant to BZ and that the gene of TcI BZ-resistant strains exhibited several single nucleotide polymorphisms (SNPs) as compared to the gene of CL Brener BZ-susceptible strain. Here we report the sequence of TcABCG1 gene of fourteen T. cruzi strains, with diverse degrees of BZ sensitivity and belonging to different discrete typing units (DTUs) and Tcbat group. Although DTU-specific SNPs and amino acid changes were identified, no direct correlation with BZ-resistance phenotype was found. Thus, it is plausible that the transporter abundance is a determinant factor for drug resistance, as pointed out above. Sequence data were used for Bayesian phylogenies and network genealogy analysis. The network showed a high degree of reticulation suggesting genetic exchange between the parasites. TcI and TcII clades were clearly separated. Tcbat sequences were close to TcI. A fourth clade clustered TcABCG1 haplotypes of TcV, TcVI and TcIII strains, with closer proximity to TcI. Analysis of the recombination patterns indicated that hybrid strains contain haplotypes that are mosaics most likely derived by intragenic recombination of parental sequences. The data confirm that TcII and TcIII as the parentals of TcV and TcVI DTUs. Since genetic fingerprint of TcI was found in TcIII, we sustain the previously proposed "Two Hybridization model" for the origin of hybrid strains. Among the twenty best BLASTP hits in databases, orthologues of TcABCG1 transporter were found in Leishmania spp. and African trypanosomes, though their function remains undescribed.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Drug Resistance , Genes, Protozoan , Nitroimidazoles/pharmacology , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/genetics , Amino Acid Sequence , Cloning, Molecular , Genetic Variation , Molecular Sequence Data , Parasitic Sensitivity Tests , Phylogeny , Polymorphism, Genetic , Recombination, Genetic , Sequence Analysis, DNA
15.
Eur J Pharmacol ; 742: 139-44, 2014 Nov 05.
Article in English | MEDLINE | ID: mdl-25218988

ABSTRACT

Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors, with a favorable pharmacological profile. Due to its unique mechanism of action, this compound has potential application as a substitutive therapy for drug addiction. Considering that distinct neural systems subserve the addictive and analgesic actions of opioids, we tested the hypothesis that aripiprazole selectively inhibit the abuse-related, but not the antinociceptive, effects of morphine. The drugs were tested in male Swiss mice for their effects on locomotion, conditioned place preference (CPP) and nociception. Morphine (20mg/kg) increased motor activity, whereas aripiprazole (0.1, 1 and 10mg/kg) did not induce any change. This antipsychotic, however, prevented morphine-induced locomotion. In the conditioning box, aripiprazole did not induce either reward or aversion. Yet, it prevented both the acquisition and the expression of morphine-induced CPP. Finally, none of the doses of this antipsychotic interfere with morphine (5mg/kg)-induced antinociception in the tail-flick test. In conclusion, aripiprazole inhibited the abuse-related effects of morphine at doses that do not interfere with basal locomotion, reward or aversion. Also, it did not alter morphine-induced antinociceptive effects. This antipsychotic should be further investigated as a possible substitutive strategy for treating certain aspects of opioid addiction.


Subject(s)
Antipsychotic Agents/pharmacology , Central Nervous System Stimulants/antagonists & inhibitors , Morphine/antagonists & inhibitors , Piperazines/pharmacology , Quinolones/pharmacology , Animals , Antipsychotic Agents/administration & dosage , Aripiprazole , Central Nervous System Stimulants/pharmacology , Conditioning, Psychological/drug effects , Disease Models, Animal , Male , Mice , Morphine/pharmacology , Motor Activity/drug effects , Nociception/drug effects , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/physiopathology , Opioid-Related Disorders/psychology , Piperazines/administration & dosage , Quinolones/administration & dosage , Reward
16.
Article in English | MEDLINE | ID: mdl-24918088

ABSTRACT

Enolase is secreted by Candida albicans and is present in its biofilms although its extracellular function is unknown. Here we show that extracellular enolase mediates the colonization of small intestine mucosa by C. albicans. Assays using intestinal mucosa disks show that C. albicans adhesion is inhibited, in a dose dependent mode, either by pretreatment of intestinal epithelium mucosa disks with recombinant C. albicans enolase (70% at 0.5 mg/ml enolase) or by pretreatment of C. albicans yeasts with anti-enolase antibodies (48% with 20 µg antiserum). Also using flow cytometry, immunoblots of conditioned media and confocal microscopy we demonstrate that enolase is present in biofilms and that the extracellular enolase is not an artifact due to cell lysis, but must represent functional secretion of a stable form. This is the first direct evidence that C. albicans' extracellular enolase mediates colonization on its primary translocation site. Also, because enolase is encoded by a single locus in C. albicans, its dual role peptide, as glycolytic enzyme and extracellular peptide, is a remarkable example of gene sharing in fungi.


Subject(s)
Candida albicans/enzymology , Candida albicans/physiology , Intestinal Mucosa/microbiology , Phosphopyruvate Hydratase/metabolism , Animals , Cell Adhesion , Culture Media, Conditioned , Flow Cytometry , Immunoblotting , Male , Mice, Inbred BALB C , Microscopy, Confocal
17.
Folia Parasitol (Praha) ; 61(2): 120-32, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24822318

ABSTRACT

Gyrodactylidae and Dactylogyridae (Monogenoidea) are described or reported from three species of Characidium Reinhardt (Crenuchidae), small species of Characiformes, from streams located in southern Brazilian states. Gyrodactylus carolinae sp. n. (Gyrodactylidae) is described from the body surface of Characidium lanei Travassos (type host), C. pterostictum Gomez, and Characidium sp. from streams in the states of Paraná and São Paulo. This new species closely resembles species of Gyrodactylus von Nordmann, 1832 described from species of Poeciliidae, from which it differs by the morphology of the hooks and nucleotide sequences of ITS1-5.8S-ITS2 rDNA. Gyrodactylus inesperatus sp. n. is described from the body surface of Characidium sp. from a stream in the State of São Paulo. The latter new species is characterised by lacking a shield on the superficial bar and by the morphology of the hooks, both unique characteristics for Neotropical species of Gyrodactylus. Marumbius gen. n. (Dactylogyridae) is proposed to accommodate two species, M. dorsivaginatus sp. n. from the gills of Characidium pterostictum (type host) and C. lanei, and M. amplexus sp. n. from the gills of C. lanei (all from the state of Paraná). Both species are characterised by having dorsal vagina, hook pairs 2-4, 6 and 7 composed by two subunits, hook pairs 1 and 5 lacking proximal subunit, and by the length of proximal subunits (when present) varying among hook pairs, completely or partially overlapping gonads, and male copulatory organ (MCO) represented by an incomplete coil of a sclerotized tube articulated to the accessory piece by a copulatory ligament. Cacatuocotyle paranaensis Boeger, Domingues et Kritsky, 1997 is reported from C. lanei at low prevalence in the Rio Marumbi (state of Paraná). The Monogenoidea that parasitize species of Characidium are members of several independent lineages, some of distant evolutionary relationships, suggesting a complex origin for this parasitic fauna.


Subject(s)
Characiformes , Fish Diseases/parasitology , Trematoda/classification , Trematode Infections/veterinary , Animals , Brazil/epidemiology , Fish Diseases/epidemiology , Male , Phylogeny , Trematoda/anatomy & histology , Trematode Infections/epidemiology , Trematode Infections/parasitology
18.
Front Genet ; 4: 143, 2013.
Article in English | MEDLINE | ID: mdl-23967008

ABSTRACT

The cell invasion mechanism of Trypanosoma cruzi has similarities with some intracellular bacterial taxa especially regarding calcium mobilization. This mechanism is not observed in other trypanosomatids, suggesting that the molecules involved in this type of cell invasion were a product of (1) acquisition by horizontal gene transfer (HGT); (2) secondary loss in the other trypanosomatid lineages of the mechanism inherited since the bifurcation Bacteria-Neomura (1.9 billion to 900 million years ago); or (3) de novo evolution from non-homologous proteins via convergent evolution. Similar to T. cruzi, several bacterial genera require increased host cell cytosolic calcium for intracellular invasion. Among intracellular bacteria, the mechanism of host cell invasion of genus Salmonella is the most similar to T. cruzi. The invasion of Salmonella occurs by contact with the host's cell surface and is mediated by the type III secretion system (T3SS) that promotes the contact-dependent translocation of effector proteins directly into host's cell cytoplasm. Here we provide evidence of distant sequence similarities and structurally conserved domains between T. cruzi and Salmonella spp T3SS proteins. Exhaustive database searches were directed to a wide range of intracellular bacteria and trypanosomatids, exploring sequence patterns for comparison of structural similarities and Bayesian phylogenies. Based on our data we hypothesize that T. cruzi acquired genes for calcium mobilization mediated invasion by ancient HGT from ancestral Salmonella lineages.

20.
Infect Genet Evol ; 14: 302-12, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23279810

ABSTRACT

The opportunistic fungal pathogen Candida albicans causes serious hematogenic hospital acquired candidiasis with worldwide impact on public health. Because of its importance as a nosocomial etiologic agent, C. albicans genome has been largely studied to identify intraspecific variation and several typing methods have been developed to distinguish closely related strains. Mitochondrial DNA can be useful for this purpose because, as compared to nuclear DNA, its higher mutational load and evolutionary rate readily reveals microvariants. Accordingly, we sequenced and assembled, with 8-fold coverage, the mitochondrial genomes of two C. albicans clinical isolates (L296 and L757) and compared these sequences with the genome sequence of reference strain SC5314. The genome alignment of 33,928 positions revealed 372 polymorphic sites being 230 in coding and 142 in non-coding regions. Three intergenic regions located between genes tRNAGly/COX1, NAD3/COB and ssurRNA/NAD4L, named IG1, IG2 and IG3, respectively, which showed high number of neutral substitutions, were amplified and sequenced from 18 clinical isolates from different locations in Latin America and 2 ATCC standard C. albicans strains. High variability of sequence and size were observed, ranging up to 56bp size difference and phylogenies based on IG1, IG2 and IG3 revealed three groups. Insertions of up to 49bp were observed exclusively in Argentinean strains relative to the other sequences which could suggest clustering by geographical polymorphism. Because of neutral evolution, high variability, easy isolation by PCR and full length sequencing these mitochondrial intergenic regions can contribute with a novel perspective in molecular studies of C. albicans isolates, complementing well established multilocus sequence typing methods.


Subject(s)
Candida albicans/genetics , DNA, Mitochondrial , Genetic Drift , Genomics , Base Sequence , Candida albicans/classification , Candidiasis , DNA, Intergenic , Genetic Variation , Genome, Mitochondrial , Haplotypes , Humans , Molecular Sequence Data , Mutation , Phylogeny , Polymorphism, Single Nucleotide , Sequence Alignment
SELECTION OF CITATIONS
SEARCH DETAIL
...